Clinical Trials Browser

zipalertinib × 90 days × Clear all

NCT07601399 2026-05-22

An EAP Treatment Protocol of Zipalertinib

Carcinoma, Non-Small-Cell Lung

NCT07128199 2026-05-05

REZILIENT4

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05967689 2026-04-03

REZILIENT2

Phase 2 Recruiting

Carcinoma, Lung Diseases

NCT05973773 2026-03-10

REZILIENT3

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases